Clinical Trial Update: Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating lenvatinib plus PD-1 inhibitors as first-line therapy for unresectable or advanced biliary tract cancer is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 inhibitors

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN